| Topoisomerase IIβ–mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane YL Lyu, JE Kerrigan, CP Lin, AM Azarova, YC Tsai, Y Ban, LF Liu Cancer research 67 (18), 8839-8846, 2007 | 747 | 2007 |
| Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies AM Azarova, YL Lyu, CP Lin, YC Tsai, JYN Lau, JC Wang, LF Liu Proceedings of the National Academy of Sciences 104 (26), 11014-11019, 2007 | 361 | 2007 |
| Role of topoisomerase IIβ in the expression of developmentally regulated genes YL Lyu, CP Lin, AM Azarova, L Cai, JC Wang, LF Liu Molecular and cellular biology 26 (21), 7929-7941, 2006 | 220 | 2006 |
| A protease pathway for the repair of topoisomerase II-DNA covalent complexes A Zhang, YL Lyu, CP Lin, N Zhou, AM Azarova, LM Wood, LF Liu Journal of Biological Chemistry 281 (47), 35997-36003, 2006 | 166 | 2006 |
| Emerging importance of ALK in neuroblastoma AM Azarova, G Gautam, RE George Seminars in cancer biology 21 (4), 267-275, 2011 | 159 | 2011 |
| Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma NF Moore, AM Azarova, N Bhatnagar, KN Ross, LE Drake, S Frumm, ... Oncotarget 5 (18), 8737, 2014 | 94 | 2014 |
| Genistein induces topoisomerase IIbeta-and proteasome-mediated DNA sequence rearrangements: Implications in infant leukemia AM Azarova, RK Lin, YC Tsai, LF Liu, CP Lin, YL Lyu Biochemical and biophysical research communications 399 (1), 66-71, 2010 | 61 | 2010 |
| Role of DNA topoisomerase IIβ in neurite outgrowth A Nur-E-Kamal, S Meiners, I Ahmed, A Azarova, C Lin, YL Lyu, LF Liu Brain research 1154, 50-60, 2007 | 45 | 2007 |
| Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget. 2014; 5: 8737–49 NF Moore, AM Azarova, N Bhatnagar, KN Ross, LE Drake, S Frumm, ... Cancer Treat Rev 40, 862-71, 2014 | 6 | 2014 |
| Methods for treating neoplasia and for identifying compositions useful in such therapy LF Liu, YL Lyu, AM Azarova, JY Lau US Patent App. 14/222,863, 2014 | | 2014 |
| The ATP-competitive mTOR inhibitor Torin2 enhances sensitivity of the ALK F1174L mutation to crizotinib in neuroblastoma AM Azarova, N Bhatnagar, L Olsen-Drake, K Ross, S Frumm, Q Liu, ... Cancer Research 72 (8_Supplement), 2935-2935, 2012 | | 2012 |
| Methods for treating neoplasia and for identifying compositions useful in such therapy LF Liu, YL Lyu, AM Azarova, JYN Lau US Patent App. 12/967,261, 2011 | | 2011 |
| DNA Damage and Chromosome Rearrangements Induced by DNA Topoisomerase II-targeting Drugs A Azarova Azarova, 2007 | | 2007 |
| Topoisomerase IIB–Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxicity and Prevention by Dexrazoxane YL Lyu, JE Kerrigan, CP Lin, AM Azarova, YC Tsai, Y Ban, LF Liu | | |
